An interventional study of Movn Mobile App in Ischemic Heart Disease, Unstable Angina and Systolic Heart Failure, sponsored by University of California, San Francisco. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Angina, Unstable with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Angina, Unstable · United States.
Among the 58 studies in Angina, Unstable with a site in United States, this one is the 32nd largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2018, is one of 11 with no phase, and was the 45th registered.
328 studies on the registry are indexed under Angina, Unstable; 42 are open to participants now.
Browse Angina, Unstable studies →2 of the 58 studies in Angina, Unstable with a site in United States are open now. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+
University of Sao Paulo General Hospital · Sites in United States, Brazil
Ages 30+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Angina, Unstable studies recruiting now, 29 (85%) set no upper age limit and 3 (9%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 13 · Phase 4 5
First in 1999; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 208 across 198 interventional studies indexed under Angina, Unstable.
Median enrollment 305 across the 39 interventional studies, 500 across the 19 observational. Of the 47 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 58 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,170 studies on the registry; 370 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
University of California, San Francisco has 2 studies filed under Angina, Unstable — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Angina, Unstable with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether using a mobile app increases adherence to a heart healthy prescription after discharge from a cardiac rehab program.
Ongoing maintenance of physical activity after cardiac rehab is an important part of preventing secondary cardiac events in patients with ischemic heart disease. Our central hypothesis is that monitoring and promotion of health-related behaviors by increasing patient-provider communication through a mobile device after discharge from cardiac rehab increased adherence to a heart healthy prescription over time. Participants will be randomly assigned to use a mobile app or serve as the control group. All participants will have an activity tracker to track their activity for two months.
328 studies on the registry are indexed under Angina, Unstable; 42 are open to participants now.
This study's enrollment of 60 is below the median of 208 across 198 interventional studies indexed under Angina, Unstable.
Browse Angina, Unstable studies →University of California, San Francisco is the lead sponsor of 2,170 studies on the registry; 370 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
Compared within Angina, Unstable, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
Behavioral: Movn Mobile App
Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
Steps Per Day
Physical activity will be measured by steps per day using activity tracker.
Time frame: Two months
6MWT
Physical activity will be measured by a six minute walk test.
Time frame: 2 months
PHQ-9
Depression will be measured by the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 (lowest) to 27 (highest), higher score associated with moderate to severe depression.
Time frame: 2 months
Exercise Self-Efficacy Scale (EXSE)
Self-efficacy will be measured by the Exercise Self-Efficacy Scale (EXSE). Scores can range from 0 (lowest) to 100 (highest) with 0 indicating low self-efficacy and 100 indicating high self-efficacy.
Time frame: 2 months
Acceptability
Satification survey, scored 0 (lowest) to 5 (highest), higher score associated with greater satisfaction
Time frame: 2 months
| Milestone | MVN Group | Usual Care |
|---|---|---|
| Started | 32 | 28 |
| Completed | 26 | 25 |
| Not completed | 6 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Failed primary screening | 3 | 0 |
| Withdrew: Diagnosed with terminal cancer | 1 | 0 |
| Withdrew: Excluded from analysis | 1 | 1 |
Physical activity will be measured by steps per day using activity tracker.
| Steps/day | MVN Group | Usual Care |
|---|---|---|
| Steps Per Day | 8860 ± 5334 | 6633 ± 4684 |
Physical activity will be measured by a six minute walk test.
| meters | MVN Group | Usual Care |
|---|---|---|
| 6MWT | 430 ± 112 | 429 ± 97 |
Depression will be measured by the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 (lowest) to 27 (highest), higher score associated with moderate to severe depression.
| score on a scale | MOVN | Usual Care |
|---|---|---|
| PHQ-9 | 1 (0 to 3) | 2 (0 to 3) |
Self-efficacy will be measured by the Exercise Self-Efficacy Scale (EXSE). Scores can range from 0 (lowest) to 100 (highest) with 0 indicating low self-efficacy and 100 indicating high self-efficacy.
| score on a scale | MVN Group | Usual Care |
|---|---|---|
| Exercise Self-Efficacy Scale (EXSE) | 10 (9.9 to 10) | 9.9 (8.4 to 10) |
Satification survey, scored 0 (lowest) to 5 (highest), higher score associated with greater satisfaction
| Score on a scale | MVN Group | Usual Care |
|---|---|---|
| Fitbit device | 4.83 ± 0.41 | — |
| Movn app | 4.5 ± 0.71 | — |
Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MVN Group | 0/32 (0%) | 1/32 (3.1%) | 0/32 (0%) |
| Usual Care | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Event | MVN Group | Usual Care |
|---|---|---|
| Terminal cancer diagnosis unrelated to studyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/32 | 0/28 |
We enrolled 60 individuals; however, 9 withdrew or were lost to follow-up (6 from the intervention group and 3 from the control group), representing 15% (9/60) attrition.
| Age, Categorical(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 11 | 22 |
| >=65 years | 15 | 14 | 29 |
| Age, Continuous(years) | MVN Group | Usual Care | Total |
|---|---|---|---|
| Mean | 66.7 ± 8.6 | 66.8 ± 8.7 | 66.8 ± 8.7 |
| Sex: Female, Male(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| Female | 6 | 5 | 11 |
| Male | 20 | 20 | 40 |
| Ethnicity (NIH/OMB)(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 25 | 23 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 19 | 22 | 41 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | MVN Group | Usual Care | Total |
|---|---|---|---|
| United States | 26 | 25 | 51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Apr 2019, 13 months.
Results were first posted in Apr 2025, 6 years after primary completion.
Of 42 non-industry interventional studies with no phase under Angina, Unstable, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 13 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →